Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...
Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...
AmplifyBio, a leading preclinical CRO and CDMO played a pivotal role in shaping discussions at Phacilitate’s Advanced Therapy Week, held January 20-23 in Dallas, Texas. As usual, the event brought ...
Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T therapy could ...
The Global Oncology Drug market was estimated at $227.2 billion in 2024 and is projected to reach $582.21 billion by 2034 , reflecting a robust CAGR of 11.67% over the forecast period from 2024 to ...
Sartorius Stedim Biotech SA / Key word (s): Dividend Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting 07-Feb-2025 ...
Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.
Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...
Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...
A California federal district court denied Gilead Sciences, Inc. and Kite Pharma, Inc.’s motion to dismiss unpaid overtime claims under the Fair Labor Standards Act of two cell therapy specialists ...
Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback